RNAi 기술 및 세계 시장

The global market for RNAi technology is estimated to increase from $2.1 billion in 2023 to reach $4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029.

The therapeutics market for RNAi technology is estimated to increase from $1.6 billion in 2023 to reach $3.9 billion by 2029, at a CAGR of 16.2% from 2024 through 2029.

The tools and reagents market for RNAi technology is estimated to increase from $502.9 million in 2023 to reach $882.8 million by 2029, at a CAGR of 9.9% from 2024 through 2029.

Report Scope

The scope of this study encompasses an investigation of the ribonucleic acid interference (RNAi) technology market. BCC Research analyzes RNAi technology based on technology type: tools and reagents, diagnostics, therapeutics, and agriculture. BCC Research determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next six years. The report provides a detailed analysis of the market's drivers, restraints, challenges, and opportunities. It includes company profiles of key players, with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides detailed information on emerging technologies and new developments in the market; examines the regulatory landscape; provides a patent and pipeline analysis; and discusses ESG developments, the investment outlook, and deals within the market.

Report Includes

• 26 data tables and 53 additional tables
• An overview of the global market for RNAi technologies
• Analysis of global market trends, featuring revenue data for 2021- 2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
• Evaluation of the current market's size and revenue growth prospects, along with a market share analysis by type, therapeutic area, delivery method, and region
• A look at innovations, technological advances, and recent product launches in the RNAi market
• Analysis of the industry's regulatory framework and policies
• A discussion of ESG challenges and ESG practices in the RNAi technologies industry
• An analysis of the key companies' market shares, proprietary technologies, and strategic alliances
• Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Novartis AG, Thermo Fisher Scientific Inc., and Revvity Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Background: Genetic Material
• RNA Interference Overview
• RNA Interference: Mechanism of Action
• Initiation Phase
• Effector Phase
• Small Interfering RNAs (siRNAs)
• MicroRNAs (miRNAs)
• Small Hairpin RNAs (shRNAs)

Chapter 3 Market Dynamics

• Global Market Dynamics
• Market Drivers
• Increasing Prevalence of Chronic Disease
• Increasing Approval of RNAi Products
• Advancements in RNAi Delivery Systems
• Increasing Strategic Initiatives
• Convenient Dosing
• Market Restraints
• High Treatment Costs
• Lack of Awareness
• Market Opportunities
• Expansion of Disease Targets
• Combination Therapies
• Untapped Genetic Targets

Chapter 4 Emerging Technologies and Developments

• Therapeutics
• Diagnostics
• Circulating miRNA Diagnostics for Non-invasive Health Monitoring
• Agriculture

Chapter 5 Pipeline Analysis

Chapter 6 Patent Analysis

• Patent Analysis

Chapter 7 Market Segmentation Analysis

• Segmentation Breakdown
• Overview
• Market Analysis by Technology
• Therapeutics
• RNAi Therapeutics Market, by Region
• RNAi Therapeutics Market, by Therapeutic Area
• RNAi Therapeutics Market, by Delivery Method
• Diagnostics
• Reagents and Tools
• Agriculture
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Emerging Markets

Chapter 8 Competitive Intelligence

• Strategic Initiatives
• Competitive Analysis

Chapter 9 Sustainability in RNAi Technology Market: An ESG Perspective

• Introduction to ESG
• Sustainability in RNAi Technology Industry: An ESG Perspective
• Environmental Initiatives
• Social Initiatives
• Governance Initiatives
• Case Study
• Concluding Remarks from BCC

Chapter 10 Appendix

• Methodology
• Acronyms
• Sources
• Company Profiles
• ALNYLAM PHARMACEUTICALS INC.
• ARROWHEAD PHARMACEUTICALS INC.
• ARBUTUS BIOPHARMA CORP.
• BAYER AG
• MERCK KGAA
• NOVARTIS AG
• NOVO NORDISK A/S
• OLIX PHARMACEUTICALS INC.
• QIAGEN
• REVVITY INC.
• SILENCE THERAPEUTICS
• SIRNAOMICS
• SYLENTIS S.A.
• SWITCH THERAPEUTICS
• THERMO FISHER SCIENTIFIC INC.